Pharmafile Logo

Lucid celebrate big wins at PMEA 2015

November 26, 2015 | Awards, PMEA 2015, medical education 

Success for Lucid at PMEA 2015

Lucid group successfully supported AbbVie and Genzyme to win two awards at last night’s ceremony in London.

PEER (Psoriasis Expert Exchange FoRum) won the award for Excellence in Physicians/Healthcare Provider Support Programmes. This programme focussed on changing clinical behaviour on a global scale to improve standards of care in the management of psoriatic disease.

Commenting on the award, the judges said “The work around the Psoriasis Expert Exchange FoRum [PEER] showed an excellent understanding of the market and took a patient-centred approach from the outset. This was an ambitious programme reaching 3,200 physicians in 25 countries that achieved behavioural change which resulted in improved patient outcomes. A very comprehensive, sophisticated programme with great penetration. Congratulations to the AbbVie team.”

- PMLiVE
PEER epitomises Lucid group’s dedication to changing behaviour and improving patient outcomes.

Lucid also supported AbbVie to win the highly commended award in this category for its Treat to Target UK (T2TUK) programme. This programme focussed on driving implementation of the T2TUK recommendations across the UK.
 
And they celebrated with Genzyme after supporting them to win the award for launch excellence.

Lucid group were also proud to sponsor the award for Excellence in Continuous Development: Education Services for Global or Emerging Markets, which was won by Novo Nordisk for their Changing Diabetes in Children programme.

Dennis O’Brien Lucid group CEO commented 
“we are lucky to have a group of talented clients, who truly work in partnership with us to build programmes that make a difference.  It was great to be able to support them in their work and to celebrate their success with them”

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD